2008
DOI: 10.1021/jm701440h
|View full text |Cite
|
Sign up to set email alerts
|

Structure−Antitussive Activity Relationships of Naltrindole Derivatives. Identification of Novel and Potent Antitussive Agents

Abstract: We have previously reported antitussive effects of naltrindole (NTI), a typical delta opioid receptor antagonist, in a rat model. The ED50 values of NTI by intraperitoneal and peroral injections were 104 microg/kg and 1840 microg/kg, respectively, comparable to those of codeine. Codeine, one of the most reliable centrally acting antitussive drugs, has micro agonist activity and thus the same side effects as morphine, e.g., constipation, dependency, and respiratory depression. Because NTI is a delta opioid anta… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
5
0

Year Published

2010
2010
2019
2019

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 24 publications
(5 citation statements)
references
References 30 publications
0
5
0
Order By: Relevance
“…The 5-isocyanate analog of NTI, 59-NTII, was the first irreversible nonpeptide DOPr antagonist (Portoghese et al, 1990), which produced long-lasting antagonism of the antinociceptive effects of the DOPr2 agonists DSLET and deltorphin II but not of that of the DOPr1 agonist DPDPE (Jiang et al, 1991;Vanderah et al, 1994). The NTI derivative 9R,13S,2,quinolino [29,19:6,7]morphinan-14-ol(1b) methanesulfonate] showed moderate DOPr binding affinity and DOPr partial agonist activity (Sakami et al, 2008b). A TRK-850 analog, TRK-851 [(5R,9R,13S,14S)-17-cyclopropylmethyl-6,7-didehydro-4,5-epoxy-89-fluoro-59,69-dihydro-49H-pyrrolo[3,2,1-ij]quinolino [29,19:6,7]morphinan-3,14-diol(1c) methanesulfonate], also showed DOPr antagonist properties and was metabolically more stable (Sakami et al, 2008a).…”
Section: B D-opioid Receptor Antagonistsmentioning
confidence: 99%
“…The 5-isocyanate analog of NTI, 59-NTII, was the first irreversible nonpeptide DOPr antagonist (Portoghese et al, 1990), which produced long-lasting antagonism of the antinociceptive effects of the DOPr2 agonists DSLET and deltorphin II but not of that of the DOPr1 agonist DPDPE (Jiang et al, 1991;Vanderah et al, 1994). The NTI derivative 9R,13S,2,quinolino [29,19:6,7]morphinan-14-ol(1b) methanesulfonate] showed moderate DOPr binding affinity and DOPr partial agonist activity (Sakami et al, 2008b). A TRK-850 analog, TRK-851 [(5R,9R,13S,14S)-17-cyclopropylmethyl-6,7-didehydro-4,5-epoxy-89-fluoro-59,69-dihydro-49H-pyrrolo[3,2,1-ij]quinolino [29,19:6,7]morphinan-3,14-diol(1c) methanesulfonate], also showed DOPr antagonist properties and was metabolically more stable (Sakami et al, 2008a).…”
Section: B D-opioid Receptor Antagonistsmentioning
confidence: 99%
“…Such conflicting results may be explained by the different pharmacological roles of the two δ1 (inhibitory effects) and δ2 (synergistic effects) opioid receptor subtypes [1,3] and the pharmacology of the δ/µ receptor heteroligomerization [6,7]. In two recent articles, naltrindole analogs TRK-850 and -851 were reported to show promising potential for the development of a novel class of antitussive agents [8,9].…”
mentioning
confidence: 99%
“…1-Anminoindoline has been widely utilized as a chemical feedstock to access various skeletal motifs existed in numerous commercial drugs [56]. In 2014, Glorious and co-workers revealed an intermolecular catalytic method that can directly access 1-aminoindoline core [57].…”
Section: Indole Derivativesmentioning
confidence: 99%